Current Issues in Medicine
Immunology, Microbiology, Biostatistics, and Big Data
- Available for pre-order. Item will ship after June 30, 2021
The pace and sophistication of advances in medicine in the past two decades have necessitated a growing need for a comprehensive reference that highlights current issues in medicine. Each volume in the Current Issues in Medicine series is a stand‐alone text that provides a broad survey of various critical topics—all accomplished in a user-friendly yet interconnected format. The series not only highlights current advances but also explores related topics such as translational medicine, regulatory science, neglected diseases, global pandemics, patent law, immunotoxicology, ethics, theranostics, big data, artificial intelligence, novel imaging tools, combination drug products, and novel therapies. While bridging the gap between basic research, medicine, engineering, FDA law, intellectual property law, and regulatory science, the series provides a thorough understanding of medicine's potential to address health problems from both the patient’s and the provider's perspectives in a healthcare setting. The range of topics covered, and the expertise of the contributing authors accurately reflect the rapidly evolving areas within medicine—from basic medical sciences to clinical specialties. Current Issues in Medicine is essential reading for physicians, medical students, nurses, fellows, residents, undergraduate and graduate students, educators, policymakers, and biomedical researchers. The book’s multidisciplinary approach makes it a valuable reference resource for the pharmaceutical industry, academia, and governments globally. However, unlike other series on medicine or medical textbooks, this series focuses on current trends, perspectives, and issues in medicine that are central to healthcare delivery in the 21st century.Volumes 1 and 2 in this series are focused on current issues in basic medical science, subjects that are fundamental to the practice of medicine. These basic medical science subjects are traditionally taught in the first two years of medical school that precede clinical instruction and training. They provide a core of basic knowledge critical to the success in clinical medicine during rotations through surgery, internal medicine, and the other specialties of medicine. Obviously, knowledge gleaned from these subjects leads to better ways to predict, prevent, diagnose, and treat disease. Specifically, volume 2 covers immunology, microbiology, biostatistics, and big data. Clinical specialties are covered in Volume 3. Volume 4 is directed towards diagnosis and imaging techniques, volume 5 focuses on drug delivery, and volume 6 highlights novel therapeutics and clinical applications.
Table of Contents
Current Immune Aspects of Biologics and Nanodrugs: An Overview
Animal Models for Analysis of Immunological Responses to Nanomaterials: Challenges and Considerations
William C. Zamboni, Janos Szebeni, Serguei V. Kozlov, Andrew T. Lucas, Joseph A. Piscitelli, and Marina A. Dobrovolskaia
Human Clinical Relevance of the Porcine Model of Pseudoallergic Infusion Reactions
János Szebeni and Raj Bawa
Myelin Antigens and Antimyelin Antibodies
Fredrick J. Seil
Advances in the Understanding of Inflammatory Milieu and Its Correlations with Neurological Disorders
Mario Ganau, Sibel Huet, Nikolaos Syrmos, Mohammad Iqbal, Marco Meloni
Role of Ligustrum in Allergic Disease
Priyadharshini Vellore Suresh, Tania Robledo Retana, Blessy M Mani, Ana Paulina Barba de la Rosa, and Luis M Teran
Protective or Detrimental? Understanding the Role of Host Immunity in Leishmaniasis
Camila dos Santos Meira and Lashitew Gedamu
Personalized Nanomedicines for Treatment of Autoimmune Disease
Cheng Lin, Huihua Ding, Congcong Li, Nan Shen, Aimin Zhao, Matthias Bartneck
Forecasting the Novel Coronavirus COVID-19
Fotios Petropoulos and Spyros Makridakis
COVID-19 Pandemic: Implications for Dental Practitioners
Najla Dar Odeh, Hamzah Babkair, Shaden Abu-Hammad, Sary Borzangy, Abdalla Abu-Hammad and Osama Abu-Hammad
The Ocular Surface and the Coronavirus Disease 2019: Does a Dual ‘Ocular Route’ Exist?
Pietro Emanuele Napoli, Matteo Nioi, Ernesto d’Aloja, and Maurizio Fossarello
We Do Not Eat Alone: Formation and Maturation of the Oral Microbiota
Could Environment Affect the Mutation of H1N1 Influenza Virus?
Dong Jiang, Qian Wang, Zhihua Bai, Heyuan Qi, Juncai Ma, Wenjun Liu Fangyu Ding, and Jing Li
Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients?
Cristian-Marian Popescu, Aurora Livia Ursache, Gavriela Feketea, Corina Bocsan, Laura Jimbu, Oana Mesaros, Michael Edwards, Hongwei Wang, Iulia Berceanu, Alexandra Neaga, and Mihnea Zdrenghea
Knowledge, Perceptions and Practices of Community Pharmacists towards Antimicrobial Stewardship: A Systematic Scoping Review
Sajal K. Saha, Chris Barton, Shukla Promite, and Danielle Mazza
Where Cancer and Bacteria Meet
Alexandra Merlos, Ricardo Perez-Tomás, José López-López, and Miguel Viñas
A Novel Cohort Analysis Approach to Determining the Case Fatality Rate of COVID-19 and Other Infectious Diseases
Charit Samyak Narayanan
ISIDOG Recommendations Concerning COVID-19 and Pregnancy
Francesca Donders, Risa Lonnée-Hoffmann, Aristotelis Tsiakalos, Werner Mendling, José Martinez de Oliveira, Philippe Judlin, Fengxia Xue, Gilbert G. G. Donders, and ISIDOG COVID-19 Guideline Workgroup
The Unmet Medical Need for Trypanosoma cruzi-Infected Patients: Monitoring the Disease Status
Maan Zrein and Eric Chatelain
Present and Future of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections
Beatriz Suay-García and María Teresa Pérez-Gracia
Human Plague: An Old Scourge That Needs New Answers
Xavier Vallès, Nils Chr. Stenseth, Christian Demeure, Peter Horby, Paul S. Mead, Oswaldo Cabanillas, et al.
BIOSTATISTICS, ARTIFICIAL INTELLIGENCE, AND BIG DATA
Human Brain/Cloud Interface
Nuno R. B. Martins, Amara Angelica, Krishnan Chakravarthy, Yuriy Svidinenko, Frank J. Boehm, Ioan Opris, Mikhail A. Lebedev, Melanie Swan, Steven A. Garan, Jeffrey V. Rosenfeld, Tad Hogg, and Robert A. Freitas Jr
Artificial Intelligence in Drug Discovery: What Is New, and What Is Next?
Now the Future, We See Our Dreams: Artificial Intelligence in Drug Discovery
How Big Data and Artificial Intelligence Can Help Better Manage the COVID-19 Pandemic
Nicola Luigi Bragazzi, Haijiang Dai, Giovanni Damiani, Masoud Behzadifar, Mariano Martini, and Jianhong Wu
Paradigm Shift in Medicinal Chemistry towards Data-Driven Approaches
The Importance of Proper Statistical Methods in Developing Robust Predictive Models Using Chemodescriptors and Biodescriptors in the Twenty First Century
Subhash C. Basak
Fit-for-Purpose?’—Challenges and Opportunities for Applications of Blockchain Technology in the Future of Healthcare
Tim K. Mackey, Tsung-Ting Kuo, Basker Gummadi, Kevin A. Clauson, George Church, Dennis Grishin, Kamal Obbad, Robert Barkovich, and Maria Palombini
Feasibility of a mHealth Approach to Nutrition Counseling in an Appalachian State
Melissa D. Olfert, Makenzie L. Barr, Rebecca L. Hagedorn, Dustin M. Long, Treah S. Haggerty, Mathew Weimer, Joseph Golden, Mary Ann Maurer, Jill D. Cochran, Tracy Hendershot, Stacey L. Whanger, Jay D. Mason and Sally L. Hodder
EDITORIALS AND PERSPECTIVES
A Future Perspective for Regenerative Medicine: Understanding the Concept of Vibrational Medicine
Burnout and Doctors: Prevalence, Prevention and Intervention
Fungal Diseases as Neglected Pathogens: A Wake-Up Call to Public Health Officials
Marcio L. Rodrigues and Joshua D. Nosanchuk
Survey on Open Peer Review: Attitudes and Experience amongst Editors, Authors and Reviewers
Tony Ross-Hellauer, Arvid Deppe, and Birgit Schmidt
The Common Ground of Open Access and Interdisciplinarity
China’s Illegitimate Game of Intellectual Property Theft
Animals and Patents: The Mouse That Went to Harvard!
Simultaneous Dengue and COVID-19 Epidemics: Difficult Days Ahead
Mathieu Nacher, Maylis Douine, Mélanie Gaillet, Claude Flamand, Dominique Rousset, Cyril Rousseau, Chedli Mahdaoui, Stanley Carroll, Audrey Valdes, Nathalie Passard, Gabriel Carles, Félix Djossou, Magalie Demar, and Loïc Epelboin
Raj Bawa, MS, PhD, is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm based in Ashburn, Virginia, USA, that he founded in 2002. Trained as a biochemist and microbiologist, he is an inventor, entrepreneur, professor, and registered patent agent licensed to practice before the US Patent & Trademark Office. He is currently a scientific advisor to Teva Pharmaceutical Industries, Ltd. (Israel), a visiting research scholar at the Pharmaceutical Research Institute of Albany College of Pharmacy (Albany, New York), and vice president and chief intellectual property officer at Guanine, Inc. (Rensselaer, New York). He has previously served as a principal investigator of National Cancer Institute SBIRs and continues to be a scientific reviewer for both the NIH and NSF. He recently (2017–2019) served as principal investigator of a CDC grant to develop an assay for Carbapenem-resistant Enterobacteriaceae. Since 2004, he has been an adjunct professor in the biology department and the Extended Learning Institute of Northern Virginia Community College (Annandale, Virginia), where he also teaches human anatomy and physiology to pre-nursing students. In the 1990s, Dr. Bawa held various positions at the US Patent & Trademark Office, including primary patent examiner from 1996–2002. Previously, he was an adjunct professor at Rensselaer Polytechnic Institute in Troy, New York from 1998–2018, where he received his doctoral degree in three years (biophysics/biochemistry).
Dr. Bawa is a life member of Sigma Xi, co-chair of the nanotech and precision medicine committees of the American Bar Association (2015–2021), and founding director of the American Society for Nanomedicine (founded in 2008). He has authored over 100 publications, co-edited 9 texts, and serves on the editorial boards of numerous peer-reviewed journals, including serving as an associate editor of Nanomedicine (Elsevier). Some of Dr. Bawa’s awards include the Innovations Prize from the Institution of Mechanical Engineers, UK (2008); Appreciation Award from the US Undersecretary of Commerce, Washington, DC (2001); the Key Award from Rensselaer’s Office of Alumni Relations (2005); and Lifetime Achievement Award from the American Society for Nanomedicine (2014).
Janos Szebeni, MD, PhD, DSc, is director of the Nanomedicine Research and Education Center at Semmelweis University in Budapest, Hungary. He is also the founder and CEO of a contract research SME, SeroScience, Ltd., and a full professor of immunology and biology at the University of Miskolc in Hungary. He has held various academic positions in Hungary and abroad, including at the National Institute of Hematology and Blood Transfusion and at the First Clinics of Internal Medicine, Semmelweis University in Budapest, the University of Arizona in Tucson, AZ, the National Institute of Health in Bethesda, Maryland, Massachusetts General Hospital, Harvard University in Boston, MA, the Walter Reed Army Institute of Research in Silver Spring, Maryland. After residing in the United States for over two decades, Dr. Szebeni returned to Hungary in 2006. His research on various themes in hematology, membrane biology, nanotechnology, and immunology has produced 160+ peer-reviewed papers, book chapters, patents, etc. (citations: ≈6000, H index: 39), and a book titled The Complement System: Novel Roles in Health and Disease (Kluwer, 2004). He has made significant contributions to three fields: artificial blood, liposomes, and the complement system. His original works led to the “CARPA” concept, i.e., that complement activation underlies numerous drug-induced (pseudo) allergic (infusion) reactions.
Marina A. Dobrovolskaia, PhD, MBA, PMP, is laboratory director of operations and the head of the Immunology Section at the Nanotechnology Characterization Laboratory (NCL). In her role as the director of operations, she leads the NCL operations to provide preclinical nanoparticle characterization services to the nanotechnology research community, advance the translation of promising nanotechnology concepts from bench to the clinic, and contribute to the education of the next generation of scientists in the field of preclinical development of nanotechnology-based products, the activities emphasized in the NCL mission. She also directs the performance of Immunology, Client Relations and Administrative sections of the NCL. Closely integrated functioning of these sections plays a critical role in advancing the NCL’s key strategic goals, and in supporting the missions of the Frederick National Laboratory for Cancer Research. In her role as the Head of the Immunology Section, Dr. Dobrovolskaia leads a team conducting preclinical studies to monitor nanoparticles’ toxicity to the immune system both in vitro and in vivo using variety of immune function animal models. Prior to joining the NCL, Dr. Dobrovolskaia worked as a Research Scientist in a GLP laboratory at PPD Development, Inc. in Richmond, VA, where she was responsible for the design, development and validation of bioanalytical ligand-binding assays to support pharmacokinetic and toxicity studies in a variety of drug development projects. She received her M.S. degree from the Kazan State University in Russia; Ph.D. from the N.N. Blokhin Cancer Research Center of the Russian Academy of Medical Sciences in Moscow, Russia; and MBA from the Hood College in Frederick, MD. Since 2016, she is also a member of Project Management Institute and a certified Project Management Professional. Her research interests include immunology, toxicology, nanotechnology and bioanalytical methodology. Dr. Dobrovolskaia’s list of publications and citations of the published work can be accessed via the following link https://scholar.google.com/citations?user=Biz76XAAAAAJ&hl=en.
Gerald F. Audette, PhD, is associate dean of faculty in the Faculty of Science, an associate professor of chemistry, and member of the Centre for Research on Biomolecular Interactions at York University, Canada. His research focuses on the correlation between protein structure and biological activity of proteins involved in bacterial conjugation, in particular, the type 4 secretion system from the conjugative F-plasmid of Escherichia coli. In addition, his research targets the type IV pilins and associated assembly systems from several bacterial pathogens and is exploring the adaptation of these protein systems for applications in bionanotechnology and nanomedicine. Dr. Audette is the co-editor of volumes 1–4 of the Jenny Stanford Series on Nanomedicine and is a subject editor of structural chemistry and crystallography for the journal FACETS.
Brian E. Reese, PhD, JD, MBA, is a principal at Choate Hall & Stewart in Boston. He has extensive experience in intellectual property (IP) law, as well as IP-related transactional matters, including licensing and long-term development and collaboration matters. Dr. Reese primarily practices in the life sciences sector, and his combination of technical, legal, and business expertise allow him to provide unusually comprehensive and pragmatic strategic counsel to his practice. As a former stock analyst, Dr. Reese has a strong appreciation for the business realities his clients face as well as how IP and corporate transactions can help them achieve their objectives.
Dr. Reese graduated with a BS in cellular biochemistry from the State University of New York at Plattsburgh. He subsequently obtained his PhD from the Pennsylvania State University for his research in the areas of neuroscience, molecular biology and toxicology, while also completing his MBA at Penn State. Dr. Reese attended Albany Law School in Albany, NY and graduated magna cum laude. As a trained neuroscientist, Dr. Reese has authored several scientific and legal research papers in peer-reviewed journals. Dr. Reese is active in providing pro bono services in intellectual property for several entities in the Boston area and currently serves as co-chair of the American Bar Association’s Nanotech Committee.